News

2015 POZEN News Archive

Keyword Search
 
2015 | 2014 | 2013
DateTitle 
12/28/15POZEN Announces Effectiveness Of Aralez Registration Statement On Form S-4 And Provides Update On Key Milestones For 2016
-POZEN schedules stockholder meeting for February 2, 2016-  -Plan to re-file YOSPRALA™ New Drug Application early in the second quarter; Approval and launch targeted in fourth quarter-  CHAPEL HILL, N.C., Dec. 28, 2015 /PRNewswire/ -- POZEN Inc. ("POZEN") (NASDAQ: POZN) today announced that the registration statement on Form S-4 filed by Aralez Pharmaceuticals Inc. ("Aralez") on December 14, 2015 with the U.S. Securities and Exchange Commission (SEC) has been declared effectiv... 
Printer Friendly Version
12/07/15POZEN And Tribute Announce Plan To Proceed With Merger To Form Aralez Pharmaceuticals
-US$350 Million Capital Commitment from Deerfield-Led Syndicate- -Canada Domicile Provides Similar Competitive Structure and Benefits to Ireland- -Previously Scheduled Shareholder Meetings of POZEN and Tribute to be Rescheduled- CHAPEL HILL, N.C. and MILTON, Ontario, Dec. 7, 2015 /PRNewswire/ -- POZEN Inc. ("POZEN") (NASDAQ: POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute") (TSX VENTURE:TRX) (OTCQX International:TBUFF) today confirmed their merger plans and announced that they... 
Printer Friendly Version
11/23/15POZEN And Tribute Provide Update On Pending Combination Transactions
-POZEN and Tribute Evaluating Canadian Domicile for Aralez Pharmaceuticals- CHAPEL HILL, NORTH CAROLINA and MILTON, ONTARIO -- (Marketwired) -- 11/23/15 -- POZEN Inc. ("POZEN") (NASDAQ:POZN) and Tribute Pharmaceuticals Canada Inc. ("Tribute") (TSX VENTURE:TRX) (OTCQX:TBUFF) today provided an update on their pending combination transactions. The companies have reviewed the recent guidance from the U.S. Treasury's Notice 2015-79 issued on November 19, 2015 and its potential impact on the propos... 
Printer Friendly Version
11/09/15POZEN Reports Third Quarter 2015 Results
Strategic Merger with Tribute Pharmaceuticals Still on Track to Close in December 2015 Commercial Launch Preparation Efforts for YOSPRALATM Well Underway CHAPEL HILL, N.C.--(BUSINESS WIRE)--Nov. 9, 2015-- POZEN Inc. (NASDAQ: POZN), today announced results for the third quarter ended September 30, 2015. The Company highlighted important corporate, commercial, and regulatory updates from the quarter. Total revenues resulting from VIMOVO® roya... 
Printer Friendly Version
10/26/15POZEN Inc. to Announce Third Quarter 2015 Results on November 9, 2015
Company to host call at 11:00 a.m. ET CHAPEL HILL, N.C.--(BUSINESS WIRE)--Oct. 26, 2015-- POZEN Inc. (NASDAQ: POZN) today announced that the Company plans to release results for the third quarter 2015 on Monday, November 9, 2015, before the opening of the U.S. markets. The Company also will conduct a conference call that day at 11:00 a.m. ET to discuss results and highlights of the third quarter of 2015. The presentation slides to be used during the call will be available on the "Investors" ... 
Printer Friendly Version
09/15/15POZEN to Present at the Ladenburg Thalmann Healthcare Conference
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Sep. 15, 2015-- POZEN Inc. (NASDAQ: POZN), a specialty pharmaceutical company, today announced that certain members of the executive management team will participate in the Ladenburg Thalmann Healthcare Conference to be held September 29, 2015 in New York. Adrian Adams, Chief Executive Officer, is scheduled to present an overview of the Company at 3:00 p.m. ET on Tuesday, September 29, 2015. The presentation will also be webcast on the POZEN website unde... 
Printer Friendly Version
09/14/15POZEN Appoints James P. Tursi, M.D. Chief Medical Officer
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Sep. 14, 2015-- POZEN Inc. (NASDAQ:POZN), today announced that James P. Tursi, M.D. will be appointed Chief Medical Officer of POZEN, effective October 1, 2015. Dr. Tursi will report to Adrian Adams, Chief Executive Officer of POZEN, and will be responsible for the oversight of the clinical operations, drug safety, medical and regulatory affairs functions. Dr. Tursi will also become Chief Medical Officer of Aralez Pharmaceuticals upon the anticipated busines... 
Printer Friendly Version
08/10/15POZEN Reports Second Quarter 2015 Results
-Strategic Merger with Tribute Pharmaceuticals Expected to Close in the 4Q 2015- -Commercialization Plans for YOSPRALATM Underway- CHAPEL HILL, N.C.--(BUSINESS WIRE)--Aug. 10, 2015-- POZEN Inc. (NASDAQ:POZN), today announced results for the second quarter ended June 30, 2015. The Company highlighted important corporate, commercial, and regulatory updates from the quarter. Total revenues resulting from VIMOVO® royalties f... 
Printer Friendly Version
07/27/15POZEN Announces August 10th Webcast of Second Quarter 2015 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (NASDAQ: POZN) announced today that it plans to release second quarter 2015 results on August 10, 2015, before the market opens. The announcement will be followed by a live webcast at 2:00 p.m. (EDT) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed on POZEN’s website at www.pozen.com and will be archived and available for r... 
Printer Friendly Version
07/27/15POZEN Appoints Scott Charles Senior Vice President of Finance
Charles to Serve as Chief Financial Officer of Aralez Following Completion of Merger with Tribute Pharmaceuticals CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jul. 27, 2015-- POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that Scott Charles will be appointed Senior Vice President of Finance of POZEN, effective July 27th, with the intention of becoming Chief Financia... 
Printer Friendly Version
06/22/15POZEN Announces Key Leadership Additions
Three New Executives, Each Bring Decades of Experience Working at High Growth Pharmaceutical Companies New Executives Will Also Serve on Leadership Team of Aralez Pharmaceuticals, Following Completion of Merger with Tribute CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 22, 2015-- POZEN Inc. (“POZEN”) (NASDAQ:POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced appointments to its Executive ... 
Printer Friendly Version
06/08/15POZEN Announces Strategic Acquisition of Tribute and Growth Capital Commitment from Leading Healthcare Sponsors
Transformative Transaction Creates Premier Specialty Pharma Company Focused on Cardiovascular Treatments US$350 Million Capital Commitment from Deerfield-Led Syndicate to Fund Commercial Launch and Pursue Strategic Acquisitions and Growth Opportunities Adrian Adams Will Lead World-Class Management Team with Record of Growth and Innovation CHAPEL HILL, N.C. & MILTON, Ontario--(BUSINESS WIRE)--Jun. 8, 2015-- POZEN Inc.... 
Printer Friendly Version
06/02/15POZEN Forms an Irish Subsidiary and Enters into an Intangible Property Transfer Arrangement
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 2, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that it has formed POZEN Limited, a wholly owned Irish subsidiary and has entered in an Intangible Property Transfer Arrangement between POZEN Inc. and POZEN Limited. The company has been evaluating its strategic options since recovering the U.S. commercial rights on ... 
Printer Friendly Version
06/01/15POZEN Announces Retirement of Founder, Chairman and CEO Dr. John R. Plachetka; Adrian Adams Named as CEO
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Jun. 1, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, effective immediately. Dr. Plachetka has also resigned from the Board of Directors of POZEN and has withdrawn as a nominee for election as a director at the 2015 Annual Meetin... 
Printer Friendly Version
05/08/15POZEN Reports First Quarter 2015 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--May 8, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the first quarter ended March 31, 2015. Corporate Highlights Q1 2015 was the fourth consecutive quarter of positive cash flow. Royalty revenue for Q1 2015 was $4.4 million compared to $4.5 million for Q1 2014. ... 
Printer Friendly Version
05/04/15POZEN Announces May 8th Webcast of First Quarter 2015 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--May 4, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release first quarter 2015 results on May 8, 2015, before the market opens. The announcement will be followed by a live webcast at 10:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcast can be accessed... 
Printer Friendly Version
03/09/15POZEN Reports Fourth Quarter and Year End 2014 Results
- Reports Annual Net Income of $19.7 Million, Including VIMOVO Royalty of $21.1 Million - - Updates Anticipated Commercialization Timing - CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar. 9, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2014. Corporate Highlights ... 
Printer Friendly Version
03/04/15POZEN Announces March 9th Webcast of Fourth Quarter and Year End 2014 Results
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Mar. 4, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, announced today that it plans to release fourth quarter and year end 2014 results on March 9, 2015, before the market opens. The announcement will be followed by a live webcast at 11:00 a.m. (ET) with a discussion by POZEN management of the earnings and business results. The webcas... 
Printer Friendly Version
02/04/15POZEN Announces Issuance of VIMOVO® Related Patent by the United States Patent and Trademark Office
CHAPEL HILL, N.C.--(BUSINESS WIRE)--Feb. 4, 2015-- POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced the issuance of a patent by the United States Patent and Trademark Office (USPTO) entitled “Method for Treating a Patient at Risk for Developing an NSAID-associated Ulcer” that relates to VIMOVO® (naproxen/esomeprazole magnesium) delayed release tablets in patients taking l... 
Printer Friendly Version
Data provided by Nasdaq. Minimum 15 minutes delayed.